Home Cart Sign in  
Chemical Structure| 577953-88-9 Chemical Structure| 577953-88-9

Structure of Montelukast dicyclohexylamine
CAS No.: 577953-88-9

Chemical Structure| 577953-88-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Montelukast dicyclohexylamine is an efficient, selective, and orally active cysteinyl leukotriene receptor 1 (CysLT1) antagonist, suitable for research on asthma prevention and liver injury.

Synonyms: MK0476 dicyclohexylamine

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Montelukast dicyclohexylamine

CAS No. :577953-88-9
Formula : C47H59ClN2O3S
M.W : 767.50
SMILES Code : O=C(O)CC1(CS[C@@H](C2=CC=CC(/C=C/C3=NC4=CC(Cl)=CC=C4C=C3)=C2)CCC5=CC=CC=C5C(C)(O)C)CC1.C6(NC7CCCCC7)CCCCC6
Synonyms :
MK0476 dicyclohexylamine
MDL No. :MFCD23160308

Safety of Montelukast dicyclohexylamine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H319
Precautionary Statements:P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293T/hACE2+TMPRSS2 1-50 μM 72 hours To evaluate the inhibitory effect of Montelukast on SARS-CoV-2 pseudovirus entry into HEK293T/hACE2+TMPRSS2 cells. Results showed that Montelukast at 50 μM effectively neutralized the pseudovirus, delaying viral activity by 20 hours. Mol Ther. 2022 Feb 2;30(2):963-974
Human naïve CD4+ T cells 0.2 μM, 2 μM, 20 μM 72 hours To evaluate the effect of Montelukast on the differentiation of human naïve CD4+ T cells into Th17 cells, results showed that Montelukast inhibited Th17 cell differentiation in a dose-dependent manner and suppressed NF-κB signaling. Int J Biol Sci. 2024 Mar 25;20(6):2168-2186
HaCaT keratinocytes ≤10 μM 48 hours To evaluate the effect of Montelukast on M5-induced keratinocyte proliferation, results showed that Montelukast significantly inhibited keratinocyte proliferation and modulated the NF-κB signaling pathway. Int J Biol Sci. 2024 Mar 25;20(6):2168-2186
BEAS-2B cells 10 μM 24 hours To evaluate whether CysLTs directly affect Nrf2 nuclear translocation, results showed montelukast did not influence Nrf2 translocation Br J Pharmacol. 2017 Oct;174(19):3346-3358

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice RSV infection model Oral 30 mg/kg Once daily, from 1 day before primary or secondary infection through Day 6 after infection To evaluate the effects of Montelukast on RSV-induced AHR and airway inflammation. Results showed that Montelukast administered during primary infection reduced AHR and airway inflammation and increased IFN-γ production. Am J Respir Crit Care Med. 2010 Aug 15;182(4):455-63
Sprague Dawley rats and athymic nude rats Quinolinic acid-induced striatal neurotoxicity model Intraperitoneal injection 1 or 10 mg/kg Once daily for 14 days To evaluate the neuroprotective effects of Montelukast on QA-induced neuroinflammation and regional metabolic functions. Results showed that MLK treatment produced a significant neuroprotective effect by reducing neuroinflammation assessed by immunofluorescence and preserving regional brain metabolism and metabolic connectivity from QA-induced neurotoxicity in cortical and subcortical regions. J Neuroinflammation. 2023 Feb 13;20(1):34
BALB/c mice IMQ-induced psoriasis-like murine model Topical application (cream), intraperitoneal injection (solution) 30 mg (cream group), 10 mg/kg (i.p. injection group) Once daily for 6 days To evaluate the therapeutic effect of Montelukast on IMQ-induced psoriasis-like murine model, results showed that Montelukast significantly reduced PASI scores, decreased inflammatory cell infiltration, and suppressed NF-κB signaling pathway. Int J Biol Sci. 2024 Mar 25;20(6):2168-2186
Mice Juvenile mouse brain irradiation injury model Intraperitoneal injection 10 mg/kg Once daily for 4 or 14 days Montelukast reduced radiation-induced cell death in the acute phase and altered the number of neurons in the granule cell layer during the sub-acute phase. Under normal conditions, Montelukast decreased proliferation in the hippocampus. Cell Death Dis. 2018 Jul 10;9(7):775
Male CD-1 mice Inflammation-induced preterm brain injury model Intraperitoneal injection 1–30 mg/kg Twice daily from P1–4, once on P5, followed by daily administration for a further 5 days Montelukast attenuated both peripheral and central inflammation, reducing the expression of pro-inflammatory molecules (IL-1β, IL-6, TNF) in the brain. Inflammation induced a reduction in parvalbumin-positive interneuron density in the cortex, which was normalised with high-dose montelukast. The lowest effective dose, 3 mg/kg, improved anxiety and spatial learning deficits in this model of inflammatory injury, and alterations in cortical mean diffusivity were not present in animals that received this dose of montelukast. J Neuroinflammation. 2022 Oct 29;19(1):265
BALB/c mice Chlorine-induced airway hyperresponsiveness model Oral gavage 3 mg/kg Three doses: 24 h and 1 h before chlorine exposure, and 1 h before outcome measurement Montelukast pretreatment attenuated chlorine-induced AHR and inflammation, reduced neutrophil and eosinophil influx in BAL fluid, and decreased IL-6 and VEGF levels Br J Pharmacol. 2017 Oct;174(19):3346-3358

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.30mL

0.26mL

0.13mL

6.51mL

1.30mL

0.65mL

13.03mL

2.61mL

1.30mL

 

Historical Records

Categories